Exact Sciences consensus stays constructive, analysts see upside for the shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 14:04.

Exact Sciences (US30063P1057) remains firmly covered on NASDAQ, with analysts still expecting upside from current levels. Consensus data for the stock shows a predominantly positive stance and a target price that sits above the latest closing print.

What analysts are signaling

For Exact Sciences, MarketScreener aggregates 29 analyst ratings, with a majority in the Buy camp and a smaller group on Hold and Sell according to its latest consensus overview. MarketScreener consensus for Exact Sciences The same overview points to an average 12-month price target around 105 US dollars, implying moderate upside versus the recent NASDAQ close near that level.

INDmoney cites a very similar picture, mentioning an average target of 105.81 US dollars compared with a referenced share price of 104.94 US dollars, based on 29 analyst opinions as of March 2026. INDmoney data on Exact Sciences targets and ratings The diagnostics group sits in a medtech peer universe with established players such as Abbott Laboratories and Danaher, where investors often compare growth, margins and spending on innovation.

How the stock is valued on NASDAQ

Recent price data from INDmoney show Exact Sciences shares quoted at 104.94 US dollars, with the session range between 104.90 and 104.98 US dollars and a daily gain of 0.98 percent at that point in March 2026. INDmoney quote snapshot for EXAS on NASDAQ That level keeps the stock close to the consensus target band, suggesting that fresh catalysts from earnings or pipeline news will be important for the next move.

On valuation, analyst compilations typically show Exact Sciences trading at a premium to many diversified healthcare names because of its growth profile in cancer diagnostics, but at a discount to some high-growth biotech stories where products are still largely in development. MarketScreener valuation and peer comparison for Exact Sciences For investors who track the S&P 500 health-care segment, the stock often serves as a more focused bet on screening technologies alongside broader groups like Abbott and Thermo Fisher.

The diagnostics products behind the stock

Exact Sciences generates most of its revenue with cancer-related diagnostic tests, led by Cologuard, a noninvasive stool DNA test for colorectal cancer screening that is widely used in the United States. The company also offers Oncotype DX genomic tests that help guide treatment decisions in breast and other cancers and continues to invest in new screening technologies using blood and other biomarkers.

Where the shares trade today

The Exact Sciences shares (US30063P1057) most recently traded on NASDAQ at 104.94 US dollars in March 2026, based on INDmoney price data timestamped around 2026-03-21, 06:59 IST, which corresponds to the closing region that day in New York.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a recommendation to buy or sell any financial instrument. Investors should conduct their own research and consider their individual financial situation before making investment decisions.